| Management target | Revenue 45.0% FY27 |
|---|
| Revenue growth | 47% YoY growth to record ₹613 Cr revenue. |
|---|---|
| Margins | EBITDA margins improved to 22.2% from 17.7% YoY. |
| Demand visibility | Strong visibility in CDMO; Xanthine impacted by shipping delays. |
| Management confidence | Confident, emphasizing multi-pillar strategy and transition to CDMO leadership. |
Growth
Revenue grew 47% YoY to ₹613 Cr; EBITDA surged 84% led by CDMO and Steroid API expansion.
Outlook
Targeting 40-50% CDMO growth and ₹1,000 Cr CDMO revenue in 2-3 years.
Risks
Rising debt (₹650 Cr), elevated working capital cycles (165 days), and geopolitical raw material cost volatility.
Earnings Call Transcript filed with NSE, NSE: AARTIPHARM. Summary written with AI assistance from the document.
Aarti Pharmalabs Ltd: key numbers
- Share price
- ₹872.70
- Market cap
- ₹7,914 Cr
- Revenue (annual)
- ₹1,819 Cr
- Net profit (annual)
- ₹174.7 Cr
- P/E (TTM)
- 30.8×Sector 45.9×
- Promoter holding
- 39.66%-3.20% QoQ
- FII holding
- 8.16%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aarti Pharmalabs Ltd
All →Aarti Pharmalabs Investor Presentation: Key Takeaways
Q2 FY27 standalone revenue INR 6,126Mn (+46.8% YoY), EBITDA INR 1,358Mn (22.2% margin), PAT INR 658Mn (+180% YoY). H1 revenue +44.7%. Xanthine capacity expansion and Atali capex drive growth.
Aarti Pharmalabs Management Change
Aarti Pharmalabs accepted CFO Piyush Lakhani's resignation, effective 30 October 2026, and appointed Vibha Thakker as CFO from 31 October 2026. The filing records a senior management change with no monetary amount.
Aarti Pharmalabs Q2 FY27 Results: Net Profit ₹71.5 Cr, Up 248.8% YoY
Aarti Pharmalabs Ltd reported revenue from operations of ₹610.5 Cr (+45.9% YoY) and net profit of ₹71.5 Cr (+248.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹71.5 Cr · +248.8% YoY
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.